The signaling events involved in the onset of ovarian cancer from the fallopian tube epithelium (FTE) are crucial for early detection and treatment of the disease, but they remain poorly defined. Conditional homozygous knockout of PTEN mediated by PAX8-cre recombinase was sufficient to drive endometrioid and serous borderline ovarian carcinoma, providing the first model of FTE-derived borderline tumors. In addition, heterozygous PTEN deletion in the FTE resulted in hyperplasia, providing a model to study early events of human ovarian pathogenesis. To uncover the mechanism underlying the invasion of cancerous oviductal cells to the ovary, PTEN-deficient murine oviductal cells were developed and tagged with green fluorescent protein. Loss of PTEN increased cell migration, invasion, and upregulated WNT4, a key regulator of Müllerian duct development during embryogenesis. Further investigation revealed that WNT4 was required for increased migration and colonization of the ovary by PTEN-deficient oviductal cells in a β-catenin independent manner. Human tumor microarrays and ovarian cancer cells lines confirmed WNT4 expression in cancer and its role in migration. Together, these findings provide a novel model to study the mechanism of fallopian tube tumor initiation and invasion to the ovary mediated by loss of PTEN, which may help to define early events of human ovarian carcinogenesis.
Introduction
Epithelial ovarian cancer is the most lethal gynecological malignancy with approximately 14,000 deaths each year in the U.S. [1] . Ovarian carcinomas are classified as Type I or Type II based on molecular and histopathological differences [2] . Type I includes low-grade serous carcinoma (LGSC), endometrioid, some clear cell, mucinous, and Brenner carcinomas; while Type II tumors include highgrade serous carcinomas (HGSC) and undifferentiated carcinomas [2] . Type II tumors harbor TP53 mutations [3] that can typically be visualized by immunohistochemistry (IHC), termed the "p53 signature", and have a higher propensity for metastasis [2] .
Evidence suggests that HGSC can originate from the fallopian tube epithelium (FTE) [4] [5] [6] . In fact, early precancerous lesions have been identified in the fallopian tubes, but not in the ovaries, of women with HGSC and in women at high risk of getting HGSC (bearing BRCA1/2 mutations) [7] [8] [9] . A meta-analysis found that salpingectomy was associated with a lower risk of developing endometrioid ovarian cancer and HGSC [10] . Endometrioid ovarian cancer was recently reported to develop from both OSE and fallopian tube in murine models [11] .
LGSC arise from cystadenofibromas that progress to borderline tumors, and it may also be derived from fallopian tube mucosa [12] . Serous borderline tumors (SBTs) have been suggested as a precursor for LGSC and occasionally of HGSC; however, no current model of SBT derived from FTE has been yet reported. Better models describing different histotypes of ovarian cancer and characterizing essential drivers of tumor formation from different epithelial cell populations may improve detection, prevention, and treatment.
The importance of PTEN in high-grade serous cancer may have been underestimated. For example, over 30% of HGSC tumors present with loss of PTEN when the stromal DNA contribution is excluded [13] . IHC studies of PTEN protein levels demonstrated total loss of PTEN in 15% (including stroma) of HGSC and partial loss in another 50% [14] . To support the importance of PTEN loss in early stages of human ovarian tumorigenesis from the FTE, the loss of PTEN was found in 33% of serous tubal intraepithelial carcinoma (STIC) [15, 16] . According to the TCGA, the PI3K/AKT pathway is altered in 45% of HGSC, and this could amplify downstream signaling similarly to the loss of PTEN, such as pAKT activation [17] . PTEN mutations have also been found in about 20% of endometrioid ovarian carcinoma [18] . In addition, the knockdown of PTEN alone in murine FTE cell lines was sufficient to generate subcutaneous tumors and peritoneal colonization in athymic nude mice [9] .
Several models have helped to confirm that the FTE can give rise to different histotypes of ovarian cancer. Most murine models of FTE-derived cancer published so far require loss of PTEN, except for a model of OVGP1-driven SV40 expression in the oviduct that generated p53 stabilization, STIC and invasive adenocarcinoma [19] . A transgenic mouse model with loss of BRCA1/2, Trp53, and PTEN driven by the PAX8-Tet-on-CRE promoter, in the fallopian tube, generated HGSC [29] . A model of PTEN and Dicer deletion induced HGSC derived from FT stroma due to Amhr2-diven CRE expression [20] . In addition, OVGP1-driven conditional deletion of PTEN and APC (Adenomatous polyposis coli) led to fallopian derived endometrioid cancer, suggesting that loss of PTEN in the fallopian tube may be part of both serous and endometrioid histotypes [47] . A recent inducible murine model of OVGP1-CRE-ER driving BRCA1, Trp53, Rb1, and Nf1 inactivation generated HGSC with a long latency period compared to a model of BRCA1, Trp53 mutations and PTEN deletion [21] . However, no reports have been published demonstrating that PTEN deletion in the FTE alone is tumorigenic, thus its role in ovarian carcinoma early pathogenesis from FTE has not yet been reported and may require a stronger CRE-driven deletion in FTE. Ovariectomy in the BRCA/PTEN/p53 murine model reduces intra-abdominal metastasis from transformed fallopian tube cells, suggesting that metastasis to the ovary is a prerequisite for further metastasis to the peritoneum [22] . However, the mechanisms regulating FTE metastasis to the ovary are not known. WNT4 is essential during embryogenesis for development of the female reproductive tract [23, 24] and amplification of this locus was recently associated with increased incidence of HGSC [25] . WNT4 is enriched in stem/progenitor cells of ovarian surface epithelium and oviduct fimbria [26] and it regulates cell migration of the Müllerian duct tip [27, 28] . A spontaneous model of oviductal transformation that recapitulates aging by serial passaging expressed increased WNT4 levels, suggesting that it may be expressed during tumorigenesis [29] .
Herein, we report a new transgenic mouse model and ex vivo ovarian colonization assay to study the contribution of PTEN loss from FTE to ovarian cancer pathogenesis with the intent of uncovering precursor lesions and molecular pathways regulating primary colonization of the ovary. This transgenic model expresses a CRE-recombinase driven by PAX8 to delete a floxed PTEN allele in the FTE. We demonstrated that homozygous loss of PTEN presents with tubal derived serous borderline and endometrioid ovarian carcinoma. This is the first model to report a fallopian tubederived serous borderline cancer and, provides a model to study ovarian cancer genesis and progression from FTE. In addition, the loss of PTEN increased non-canonical WNT signaling in the FTE, which was critical for colonization of the ovary by the transformed FTE cells. These findings highlight the therapeutic potential of inhibiting the WNT non-canonical signaling pathway to decrease metastasis and invasion of the ovary by FTE-derived tumor cells, thereby blocking initial metastasis.
Results

PAX8 drives CRE-recombinase expression in the oviduct but not in the ovary
To determine if loss of PTEN alone was sufficient to generate fallopian tube-derived ovarian cancer, a conditional knockout mouse model was generated by crossing mice expressing CRE-recombinase in the fallopian tube (PAX CRE/ + ) with mice expressing the LoxP-PTEN-LoxP transgene ( Supplementary Fig. 1SA ). To validate the specificity of the model, PAX CRE/+ mice were crossed with Rosa26 mice expressing the loxP-Stop-LoxP LacZ gene. β-galactosidase staining was performed on the tissues obtained from the mice progeny. As shown in Fig. 1a , the fallopian tube expressed the enzyme, as did the kidney, which was used as the positive control. The uterus was also positive with reduced staining compared to the oviducts. As expected, the ovary did not express PAX8 validating the specificity of the model. In addition, PCR was performed to detect recombination of the floxed PTEN allele in the oviduct of the PAX8 (Fig. 1c,  Supplementary Fig. S1C ).
PAX8
CRE -driven heterozygous loss of PTEN in tubal epithelium results in hyperplasia (Fig. 2b) . The hyperplasia present in the oviduct showed expanded ducts with tubal epithelial proliferation, along with increased, disordered, and branched plica.
CRE -driven homozygous loss of PTEN in tubal epithelia is sufficient to generate SBTs and endometrioid carcinomas Histopathologic analysis revealed papillary and micropapillary growth patterns lined by mostly serous and focal mucinous epithelial proliferation. No definite stromal invasion was seen. This histology resembled human ovarian serous borderline or seromucinous tumors (Fig. 3a) . The tumors or lesions around the oviducts in homozygous mice presented the endometrioid epithelial proliferation, complex back-to-back endometrioid glands with cribriform growth patterns. Areas of squamous metaplasia were identified within endometrioid lesions (Fig. 4a) . These findings are indicative of endometrioid carcinoma (Fig. 4a ) consistent with the previously reported APC fl/fl PTEN fl/fl mouse model [11] . (Fig. S1D ). Acetylated tubulin staining was more pronounced in serous borderline than in endometrioid carcinoma (Figs. 3b and 4b). Occasional stromal invasion suggested the presence of a low-grade serous ovarian carcinoma histotype. 
Loss of PTEN results in increased migration and invasive potential of MOE cells
Our previous studies indicated that the loss of PTEN by shRNA increased migration of MOE cells in adherent conditions [9, 30] . In our transgenic model with knockout of PTEN in the FTE, clusters were observed of invasive cells in both serous and endometrioid tumors (Fig. 5a , b H&E). These cells present, at the invasive front, with stabilization of p53 and CK8 expression (Fig. 5a, b) . Consistent with previous studies [30] , MOE:PTEN shRNA cells presented increased migration in a wound healing assay ( Fig. 5c ) and increased invasion in a Boyden chamber assay ( Fig. 5d ) compared to cells MOE:SCR shRNA . Increased ovulation number is associated with an increased risk of ovarian cancer [31, 32] , leading to the hypothesis that damage during ovulation may favor invasive cells to colonize the ovary. To test if the increased migratory capability of MOE:PTEN shRNA may reflect an increased ability to invade the ovary, an ex vivo invasion assay was developed where MOE cells stably expressing GFP were incubated with murine ovaries for 24 h. Ovaries were left intact or cut with a scalpel blade to mimic the physical tearing of the ovary during ovulation (hereafter referred to as ovulation mimetic). MOE:PTEN shRNA-GFP invaded the intact and ovulation mimetic ovaries more than the MOE:SCR shRNA-GFP , suggesting that this genetic modification is sufficient to confer oviductal cells with intrinsic invasive capabilities (Fig. 5e, f) . Also, MOE:PTEN shRNA-GFP invaded the wounded ovary to a greater extent than the intact ovary, supporting the ovulation hypothesis and the importance of loss of PTEN. CRE/+ PTEN fl/fl mice using specific antibodies for CK8, WT1, acetylated tubulin (AcTUB), PAX8, Vimentin (Vim) and p53 (scale bar is 50 μm). IHC images were scored based on staining intensity: 0 = negative; 1 = faint/weak; 2 = intermediate/moderate; 3 = strong. CK8 = 3 membrane; WT1 = 3 nuclear; AcTub = 3 membrane; PAX8 2; Vim: 1 focal; p53 = 2 (50% nuclear) DAAM2 (Fig. 6a) . The WNT canonical signaling pathway was downregulated ( Supplementary Fig. S4B and Fig. 6b ), suggesting that a WNT non-canonical signaling pathway may mediate the invasive effect of PTEN loss. qPCR was used to confirm that CTNNB1 (gene encoding for β-catenin) as well as β-catenin targets LEF1 and TCF4 were not significantly regulated by loss of PTEN, whereas WNT4, DKK3, and Sdc1 were significantly up-regulated (Fig. 6c) . In addition, WNT4 and DKK3 protein levels were increased upon loss of PTEN in cell lines (Fig. 6d, e) Table S2 ).
Loss of PTEN in MOE results in alteration of the noncanonical WNT signaling
Loss of PTEN did not increase β-catenin nuclear localization in the MOE:PTEN shRNA cells (Supplementary Fig.  S3D -E) or in tumors, where β-catenin was expressed at the membrane ( Supplementary Fig. S3F ). β-catenin activation was also measured using the TOP-FLASH reporter assay and did not show any significant difference in the MOE: PTEN shRNA cells compared to MOE:SCR shRNA (Supplementary Fig. S3C ). These results indicate that canonical WNT signaling, via β-catenin, does not mediate the migratory effect of PTEN loss, but suggest that noncanonical signals might drive migration in the model.
Loss of PTEN induced migration and invasion of the ovary through non-canonical WNT signaling
The non-canonical WNT pathway has been shown to be involved in migration [27, 28] , whereas the WNT canonical pathway through β-catenin has been shown to be involved in tumor initiation but not migration nor invasion [33] . Therefore, WNT4 was tested for its ability to mediate migration in the MOE:PTEN shRNA-GFP .
LGK-974, an inhibitor of the WNT canonical and non-canonical pathways, Fig. 4 ) were seeded in the insert of a Boyden chamber and invading cells counted after 24 h (**p < 0.01). e-f Intact or ovulation mimetic ovaries from healthy mice were incubated with MOE:PTEN shRNA-GFP or MOE:SCR shRNA-GFP for 24 h. GFP positive cells were counted from more than three independent experiments (*p < 0.05; ***p < 0.001) inhibited loss of PTEN shRNA -induced invasion in a Boyden chamber assay (Fig. 7a, b) and PTEN shRNA -induced migration ( Supplementary Fig. S3I ), whereas β-catenin siRNA did not reduce PTEN shRNA -induced increased migration ( Supplementary Fig. S3G ). In addition, LGK-974 significantly reduced invasion of MOE:PTEN shRNA-GFP through ovulation mimetic ovaries (Fig. 7c, d ). However PRI724, a specific β-catenin inhibitor, did not reduce PTEN shRNA -induced invasion in a Boyden chamber assay (Fig. 7b) or invasion into the ovaries (Fig. 7e) . Finally, siRNA targeting WNT4 reduced invasion of MOE: PTEN shRNA-GFP cells into the ovary, whereas β-catenin siRNA did not (Fig. 7f) . These results indicate that loss of PTEN-induced migration and invasion is at least partially mediated by WNT4 upregulation. Since non-canonical WNT signaling may be mediated by Rac1, we tested the Rac1 inhibitor, NSC27366, and showed it reduced migration (Fig. 7j) but not invasion of the ovary (Fig. 7c) . This suggests that more investigation may be required to determine its role in loss of PTEN increased migration.
Inhibiting WNT non-canonical signaling blocks human ovarian cancer lines migration and invasion
To test whether the WNT inhibitor, LGK-974, inhibited the invasive capability of human ovarian cancer cells, OVCAR4 and OVCAR8 were infected with lentiviral particles expressing RFP and incubated with healthy ovaries in the ex vivo ovarian invasion assay. The WNT inhibitor LGK-974 reduced the human ovarian cancer lines invasion into the ovary (Fig. 7g-h ), suggesting that WNT noncanonical signaling may be required for these cells to colonize the ovary. The migratory effects of WNT4 in Drosophila M. have been attributed to activation of FAK, which is also downstream of loss of PTEN [28, 34, 35] . FAK is overexpressed in ovarian cancer and associated with poor prognosis [34, 36] . Database analysis of TCGA revealed amplification of PTK2 (gene encoding for FAK) in about 40% of samples ( Supplementary Fig. S4D ).
Furthermore, alterations of PTK2 correlate with increased FAK protein levels ( Supplementary Fig. S4E ) and reduced survival ( Supplementary Fig. S4F ). Therefore, it was relevant to test whether inhibiting FAK would block loss of PTEN-induced migration. A FAK inhibitor, SML0837, blocked the invasive capability of PTEN-depleted MOE (Fig. 7i) , and in OVCAR4 cells (Fig. 7h) , whereas the AKT inhibitor, MK2206, did not significantly change invasion (Fig. 7e) .
Discussion
Many ovarian cancers likely originate in the FTE and then colonize the ovary. A FTE-origin for some HGSC is well established and there is increasing evidence that some endometrioid cancers may also originate in the FTE [10, 11] . However, the step-wise sequence of events that coordinate FTE cell transformation and invasion of the ovary remains poorly defined and these steps are pivotal to early detection and new treatment options. Most of the previous animal models for FTE-derived ovarian cancer required loss of PTEN to induce tumorigenesis, but all of these models were engineered with multiple genetic modifications [11, 20, 37] . More interestingly, PTEN knockdown alone in the ovarian surface epithelium has been reported to be insufficient to induce tumorigenesis unless in combination with KRAS mutation or APC loss [38, 39] . Also, PTEN loss in the FTE stroma alone was not sufficient to drive tumorigenesis, and required the deletion of DICER [20] . Furthermore, a model of PTEN and APC deletion, driven by the OVGP1 promoter, generated endometrioid carcinoma from FTE [11] . In the current study, homozygous deletion of PTEN alone driven by PAX8 in the FTE was sufficient to generate endometrioid and serous borderline cancer. A previous model established that FTE can give rise to endometrioid cancer [11] , but in that model it required PTEN and APC deletion. Our model also formed endometrial carcinoma due to expression of PAX8 CRE/+ in the uterus, and therefore PTEN knockout in that tissue. However, previous models of loss of PTEN-induced endometrial carcinoma have not reported FT or ovarian involvement [40] . Furthermore, in previous models of FTE-derived HGSC, hysterectomy did not block cancer formation whereas salpingectomy did [37] . Homozygous loss of PTEN generated SBTs providing the first animal model of FTE-derived SBTs. Papillary tubal hyperplasia has been reported in patients at high risk for developing ovarian cancer [41, 42] and in low-grade SBTs [41] . Interestingly, mice with PTEN heterozygous deletion had normal ovaries but FTE lesions that resembled human hyperplasia, providing a unique model for monitoring molecular and hormonal changes required for tumor development. LGSC may 
PTEN
fl/fl were assessed for WNT4 and DKK3 protein expression. g WNT4 and FAK protein levels in a panel of human ovarian cancer lines by Western blot. h WNT4 levels in normal human fallopian tube tissues (hFT) or tissues from patients with ovarian cancer (Tissue micro array = TMA) were detected using IHC. i TMA were scored based on staining intensity: 0 = negative; 1 = faint; 2 = intermediate/moderate; 3 = strong/diffuse. SP = serous papillary; EC = endometrioid carcinoma; CC = clear cells; MC = mucinous carcinoma; PD = poorly differentiated. (*p < 0.05) originate from SBT, however, SBT resembles HGSC by presenting with loss of PAX2 [43] , suggesting that SBT may represent a precursor for HGSC. Therefore, our model provides a novel tool to study early events of hyperplasia, endometrioid carcinoma, and SBTs from the FTE.
RNAseq of MOE PTEN shRNA cells revealed enhanced expression of players in the WNT non-canonical pathway, such as WNT4, Sdc1/2, and DKK3. WNT4 was required for PTEN-induced migration, whereas β-catenin activation was not. WNT4 is of fundamental importance for Müllerian tract development and is critical for FTE cell migration during oncogenesis [27] . However, WNT4's role in reproductive cancers is unclear. In addition, a spontaneous model of oviductal cell transformation also expressed enhanced levels of WNT4, supporting its role in oviductal derived ovarian cancer [29] . An inhibitor of the WNT canonical and non-canonical pathways, LGK-974, as well as knockdown of WNT4 by siRNA, inhibited loss of PTEN induced migration, whereas inhibitors of the canonical pathway alone (PRI724) did not. This suggests that WNT4 mediates loss of PTEN-induced migration in a β-catenin independent fashion, as corroborated by the lack of β-catenin activation upon loss of PTEN in the RNAseq data, activity assays, and in tumors. Other studies have reported β-catenin nuclear localization in HGSC and it is possible that β-catenin is activated during metastatic progression. Our results are consistent with reports supporting the role of WNT4 in migration [28] . WNT4 was expressed in human ovarian cancer lines, especially in OVCAR8 and OVCAR4, and in several cancer histotypes, as revealed by the TMA analysis using IHC. Even though these lines do not present with genomic deletion or mutation of PTEN, they express WNT4 and whether PTEN expression is regulated at the protein levels is not known. Further experiments using human fallopian tube cells as controls are required to determine PTEN protein levels in HGSC cell lines.
LGK-974 also inhibited migration in the human ovarian cancer lines OVCAR4 and OVCAR8.
LGK-974 has been previously studied in primary ovarian cancer cells derived from ascites and was effective at potentiating carboplatin-induced cell death [44] . However, our studies indicate that blocking WNT4 with LGK-974 also has a role in inhibiting invasion or metastasis, particularly early metastasis to the ovary. Both loss of PTEN and WNT4 have been shown to regulate migration through activation of FAK [28] . Inhibition of FAK was able to inhibit invasion of oviductal cells and the human ovarian cancer cell OVCAR4 but not OVCAR8, suggesting that OVCAR8 cells may have acquired alterations that make them resistant to treatment. While loss of PTEN increases AKT activation [9] , an AKT inhibitor did not reduce invasion of MOE:PTEN shRNA to the ovary, suggesting that AKT may be important for survival, but not for colonization of the ovary. In support of this finding, our previous studies confirmed that myristoylated AKT was unable to induce tumorigenesis in oviductal cells [9] .
Loss of PTEN in the FTE, in both the transgenic mouse model and in the oviductal cell line model, demonstrated a significant reduction of PAX2 [30, 43] (Supplementary Fig.  S1E ). PAX2 loss is thought to be one of the earliest events in the development of HGSCs from the FTE, and it is also lost in ovarian SBTs [43] . Since the cell model harbors shRNA that reduces PTEN, while the mouse model is a full deletion, these data suggest that some reduction in PTEN, not necessarily complete loss, is sufficient to reduce PAX2 levels. In addition, stabilization of p53 protein visualized by IHC was observed in the PAX8 CRE/+ PTEN fl/fl model and in the MOE:PTEN shRNA cell line [9] . However, no downregulation of p53 mRNA or mutation was detected by RNAseq suggesting that the stabilization may be through inhibition of wild-type p53 binding to MDM2 or other mechanisms, which require further investigation. A previous murine model demonstrated that mutation of R270 was not sufficient to generate stabilization of p53 in the FTE, suggesting that other alterations may be required [45] . PAX2 and PAX8 regulate WNT4 during development [46, 47] ; however, their mechanism of regulation of WNT4 during tumorigenesis has not been studied. In the allograft model of loss of PTEN-induced tumorigenesis, the cells produced multiple tumors in the peritoneal space, whereas in the transgenic model by 7 months of age, there was no evidence of metastasis to the peritoneum. This suggests that colonization from the FT to the ovary likely occurs first, as . GFP positive cells were counted from three independent experiments and averaged (*p < 0.05). g Ovulation mimetic ovaries were incubated with OVCAR8 RFP plus DMSO or SML0837 (FAK inhibitor) for 24 h. RFP positive cells were counted from more than three independent experiments and averaged (*p < 0.05). h Ovulation mimetic ovaries were incubated with OVCAR4 RFP plus DMSO or inhibitor of FAK, SML0837, for 24 h. RFP positive cells were counted from more than three independent experiments and averaged (*p < 0.05; ***p < 0.001). i Ovulation mimetic ovaries from healthy mice were incubated with MOE: PTEN shRNA-GFP plus DMSO or inhibitor of FAK, SML0837, for 24 h. GFP positive cells were counted from three independent experiments and averaged (****p < 0.0001) also suggested recently by Coffman and Buckanovich [22] and that further alterations beyond loss of PTEN are required for metastatic progression. One possible alteration could be mutation of p53 that has been found in 96% of HGSC or as was shown in other muring models with PTEN loss in combination with loss of Rb, NF1, or BRCA [21, 37] .
Overall, our findings report for the first time that loss of PTEN alone from FTE is sufficient to induce tubal carcinoma and subsequent ovarian involvement. Furthermore, homozygous loss of PTEN generated SBTs from FTE and endometrioid carcinoma, whereas, heterozygous loss of PTEN generated hyperplasia, resembling human precursor lesions. Upregulation of the non-canonical WNT4 ligand and its signaling mediated invasion of the ovary, providing a potential novel role for inhibitors of non-canonical WNT pathway in preventing human ovarian cancer early progression.
Materials and methods
Cell culture
MOE and HGSC cell lines (OVCAR3, OVCAR4, OVCAR8, OVCAR432, KURAMOCHI, OVSAHO) were cultured as previously described [48, 49] . All lines were authenticated by STR analysis at the University of Illinois at Chicago in May 2015. MOE cell lines (originally provided by Dr. Barbara Vanderhyden, University of Ottawa) were transfected using TransIT LT1 TM with plasmids containing the gene of interest as described previously [9] . Cells expressing the shRNA #2 targeting PTEN and the new control shRNA targeting GFP was generated using shRNA from Sigma (respectively TRCN0000322487 and SHC005). siRNAs targeting WNT4 (Sigma, EMU047101), β-catenin (Sigma, EMU047621), and control (Sigma, EHURLUC) were transfected using TransIT LT1 TM . WNT inhibitors LGK-974 (14072) and PRI724 (205865) were obtained respectively from Cayman and MedKoo. The FAK inhibitor (SML0837) was obtained from Fisher. Rac1 inhibitor (NSC23766) and Akt inhibitor (MK2206) were obtained from Cayman.
Animals
All animals were treated in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and the established Institutional Animal Use and Care protocol at the University of Illinois at Chicago. The C57b/6 LoxP-PTEN-LoxP was obtained from MMHCC (Mouse Models of Human Cancer Consortium) were bred with mice expressing CRE-recombinase under control of Pax8 promoter from Research Institute of Molecular of Pathology, Vienna, Dr. Bohr-Gasse [50] . For the pathological analysis a minimum of 3-4 mice per genotype were used.
ß-galactosidase staining
The β-Galactosidase Reporter Gene Staining Kit was adapted from (Sigma GALS). Organs were washed two times with 1 mL 1X PBS, fixed and incubated for 30 min at RT on orbital rocker. After washing with PBS, organs were incubated with 1 mL of X-gal staining solution I at 37°C in a humidified incubator overnight for 18 h. Organs were then processed as for IHC.
PCR reaction to assess recombination and genotyping PCR analysis for intact PTEN was performed using primer 1 (5′ AAAAGTTCCCCTGCTGATGATTTGT-3′) and primer 2 (5′-TGTTTTTGACCAATTAAAGTAGGCTGTG-3′). To detect the recombined allele, primers 1 and 3 (5′-CCCCCAAGT-CAATTGTTAGGTCTGT-3′) were used. PCR conditions were 35 cycles (30 s at 95°C, 1 min at 55°C
, and 1 min at 72°C) using HotStarTaq Master Mix (Qiagen, Valencia, California, United States), primer (0.25 lM), and DNA (50 ng 
RNA isolation, cDNA synthesis and RT-PCR
RNA extraction was performed as described in [51] . iScript TM cDNA synthesis kit (BioRad, Hercules, CA) and SYBR green (Roche, Madison, WI) were used according to manufacturer's instructions. All qPCR runs were performed on the ABI ViiA7 (Life Technologies, San Diego, CA). Primers used are in Supplementary Table S4 .
Western blot analyses
Cells were lysed in RIPA buffer (50 mM Tris pH 7.6, 150 mM NaCl, 1% Triton X-100, 0.1% SDS) with protease (Sigma) and phosphatase inhibitors (tablets from Roche). Protein lysate (30 μg) was loaded onto a SDS-PAGE and transferred to nitrocellulose membrane. Blots were blocked with 5% milk or BSA in TBS-T and probed at 4°C overnight with primary antibodies (Supplementary Table S3 ). Anti-rabbit HRP-linked secondary antibody was used for 30 min in blocking buffer. Membranes were incubated and developed as described previously [51] .
Immunohistochemistry
Reproductive tracts and tumors were embedded in paraffin and prepared for IHC or hematoxylin and eosin stain as described in past publications [9, 48] . Tissues microarrays (TMAs) were obtained from the cooperative human tissue consortium (CHTN, Charlottesville, VA) and stained as previously described. Tissues were incubated with primary antibodies overnight (Supplementary Table S3 ). Images were acquired on a Nikon Eclipse E600 microscope using a DS-Ri1 digital camera and NIS Elements software. IHC images were scored based on staining intensity: 0 = negative; 1 = faint/weak; 2 = intermediate/moderate and the percent (%) of positive or nuclear over total is reported for Ki67 and nuclear p53, respectively.
Luciferase assay
Cells were plated in a 24 well plate (30,000 per well). The next day cells were transfected with plasmid encoding TopFlash luciferase driven by TCF-LEF binding sites and plasmid encoding β-galactosidase (100 ng each) with 0.5 μl of Mirus Transit LT1 per well in 50 μl Opti-MEM. After 20 min at RT 52 μl of transfection mixture was added dropwise to each well containing cells in 500 μl of complete medium. After 48 h cells were lysed with 120 μl of lysis buffer for luciferase activity and β-galactosidase absorbance reading was acquired as previously described [52] .
Wound healing assay
Cells were seeded at 5 × 10 4 cells per well and assay was performed after 48 h as described previously [53, 54] . Briefly, scratch was preformed, medium removed and substituted with medium containing vehicle or inhibitors. Pictures were taken right after the scratch and 8 h later using an AmScope MU900 with Toupview software (AmScope, Irvine, CA).
Boyden chamber invasion assay
Matrigel was thawed out on ice and diluted to 300 μg/ml with serum-free medium. 120 μl of diluted matrigel was added to the 0.8 μm insert of the Boyden chamber and incubated at 37°C for 1 h for matrigel to solidify. Excess of matrigel was removed from insert. Five hundred microliters of complete medium (containing 10% FBS) was added to 24 well plates at the bottom of the insert. Cells were trypsinized and collected in media with FBS. Cells were washed 2× with serum free MEM and resuspended in serum-free medium. 120 μl of MTEC4 PTEN shRNA or SCR shRNA at 1 × 10 4 cells/well was added and incubated for 24 h. Cells from the top of the insert were removed with a cotton swab. Inserts fixed with 4% PFA for 5 min, permeabilized with 70% methanol for 5 min, stained with 0.2% crystal violet in 10% ethanol for 10 min. Inserts were then rinsed 2× with PBS and dried overnight. Images of each insert were taken using AmScope MU900 with Toupview software (AmScope, Irvine, CA) and invading cells (at the bottom of the insert) were counted in ImageJ.
Ex vivo colonization assay
Ovaries were removed from day 16 or 17 day old CD1 mice and were left intact or cut with a scalpel blade to mimic ovulation (termed ovulation mimetic). Each ovary was incubated with 30,000 fluorescently labeled cells and appropriate inhibitors overnight at 37°C in an orbital shaker at speed 40. The next day ovaries were washed several times to remove non-attached cells, all observable cells were counted, and representative pictures were taken with an AmScope MU900 with Toupview software (AmScope, Irvine, CA).
Statistical analyses
All data are represented as mean ± standard error. Statistical analysis was carried out using Prism software (GraphPad, La Jolla, CA). All conditions were tested in three replicates in at least triplicate experiments. Statistical significance was determined by Student's t-test, or one-way ANOVA with Dunnett's post-hoc test. *p ≤ 0.05 was considered significant.
